Orexo AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Orexo presents data from a Phase 3 clinical trial that demonstrates that Zubsolv is as effective as Suboxone film in the treatment of opioid dependence
Orexo AB:Announces top-line data from a Phase 3 clinical trial demonstrating that Zubsolv (buprenorphine/naloxone CIII sublingual tablet) is as effective as Suboxone film in the treatment of opioid dependence.The results from a randomized, non-inferiority, multicenter, comparative trial (N=758) establish that, despite a 29 pct lower dose, Zubsolv provides equivalent efficacy compared to Suboxone film in patients who are opioid dependent.The primary endpoint of the ISTART study was retention in treatment at Day 15 with Zubsolv and Suboxone film.The study showed that there was no difference in retention in treatment at Day 15 [Zubsolv arm: 83pct (273/329); Suboxone film arm: 82.5pct (269/326)].As previously announced an additional co-primary endpoint assessed Zubsolv as a treatment for induction of buprenorphine maintenance therapy compared to generic buprenorphine monotherapy.There was no difference in retention at Day 3 [Zubsolv arm: 93.3pct (309/329); generic buprenorphine arm: 92.6pct (302/326)] in the per protocol set.Similar improvements for both groups were observed in Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), and opioid cravings VAS total scores.Physicians and patients, using the Clinical Global Impression (CGI-I) and Patient Global Impression (PGI-I) Improvement scales, reported that both treatments resulted in an average score of much improved from baseline at study end.
Latest Developments for Orexo AB
- Orexo AB completed its private placement
- Orexo AB streamlines operations in Uppsala
- Orexo AB announces positive top-line results from two phase 3 clinical trials that Assessed Zubsolv for induction of Buprenorphine Maintenance Therapy
- Orexo AB resolves on no FY 2013 dividend; authorizes share buy-back
- Share this
- Digg this